Large quantities of the drug Sotrovimab will arrive in the country next week to treat mild to moderate cases of Covid 19 to the country, Al Jarida reported.
Well-informed health sources said in a statement to the daily that it will be distributed upon arrival to hospitals specialized in treating corona to start implementing the treatment protocol through this drug.
The Ministry of Health had recently completed the contracting procedures to bring in the drug Sutrovimab as a new treatment option for Covid 19.
The sources stated that the drug Sotrovimab is from the category of monoclonal antibody drugs and is used to treat mild to moderate cases of Covid 19 in adults and children (12 years and over and weighs at least 40 kilograms) who are at risk of Covid 19 such as people who reach 65 years of age or older or who suffer from certain medical conditions, indicating that this drug is not used for Covid-19 patients who are receiving hospital treatment or who need oxygen therapy.
The sources indicated that the clinical studies of the drug Sotrovimab showed effective results, as the drug reduced the cases of hospitalization or death by 85%, and the drug is characterized by its mechanism of action, as it is a monoclonal antibody directed specifically against the barbed protein of SARS-CoV-2 and is designed to prevent Virus binding and entry into human cells.
Kuwait is the second country to license this drug globally, stressing the keenness of the Ministry of Health to provide the best and latest approved treatments for Covid 19 patients and make them available to patients in Kuwait as soon as possible after the approval of the regulatory authorities.
On the other hand, the Ministry of Health decided to cancel paper leave forms and replace them with “automated” as of today, Thursday, July 1, with the aim of raising the efficiency of administrative work by improving performance and simplifying procedures through automated systems.